Patent ID: 8088736

Claim:
A CTLA-4 polypeptide variant having improved potency or stability compared to the CTLA-4 polypeptide of SEQ ID NO: 8 comprising 4 to 10 amino acid substitutions compared to the CTLA-4 polypeptide of SEQ ID NO: 8 wherein 4 to 10 of the amino acid substitutions are selected from the following table: Position Amino acid residue 17 S, V, T 26 P 28 S 29 N 43 G 46 S 49 W, Y 54 V 59 S 61 S 62 P 66 T 70 I 71 F, L 81 R 86 V, T 94 E wherein said 4 to 10 amino acid substitutions include those at amino acid positions 26, 59, 71, and 94, wherein said improved potency is at least a 2-fold reduction in IC 50 in an assay of IL-2 production using T-cells activated by B-cells, and wherein said improved stability is at least 10% residual binding calculated as the binding signal to B7-1 or B7-2 in the presence of 10 mM DTT divided by the binding signal to B7-1 or B7-2 in the absence of DTT, multiplied by 100.